SM
AXSM icon

Sabby Management’s Axsome Therapeutics AXSM Stock Holding History

Sabby Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-81,159
Closed -$199K – 150
2018
Q1 		$199K Buy
+81,159
New +$243K 0.02% 120

Other funds holding AXSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sabby Management's AXSM Position: Q2 2018 in Review

Sabby Management sold out of Axsome Therapeutics (AXSM) in Q2 2018, closing a stake of 81,159 shares — an estimated $199K sold.

Sabby Management first reported a position in AXSM in Q1 2018 and held it in 1 quarter. The position peaked at $199K in Q1 2018. 35 funds tracked by Wall St. Rank hold AXSM as of Q2 2018.

  • Sabby Management reported no remaining Axsome Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Sabby Management sold 81,159 Axsome Therapeutics shares in Q2 2018, an estimated $199K.
  • Sabby Management first reported a position in Axsome Therapeutics in Q1 2018 and held it in 1 quarter.
  • Sabby Management's Axsome Therapeutics position peaked at $199K in Q1 2018.
  • 35 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.